Figure 5
From: Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer
(A) Three tumors/group from the first UM-UC-6 in vivo experiment were selected for H&E and IHC evaluation for EGFR, HER2, Ki67, E-cad, p-EGFR (Y1068), p-ERK (T202/Y204), p-Akt (T308, S473). Dacomitinib resulted in inhibition of EGFR (Y1068) and ERK (T202/Y204) phosphorylation, as well as reduction of E-cad expression. (B) Three tumors/group from the second UM-UC-6 in vivo experiment underwent biomarker evaluation. Dacomitinib resulted in significantly decreased p-ERK (T202/Y204) expression and staining intensity versus chemotherapy or no treatment.